LGND (Drugmakers) Stock Valuation & Fair Value Trading above its usual valuation
LGND (Drugmakers) trades at a current P/E of 33.3, about 21% above its historical normal valuation, with a forward growth estimate of 22.8% and a PEG of 1.46. Analysts' one-year estimates have been hit 18% of the time. Priced at its historical normal P/E of 27.6 on the same blended earnings, the 2026-10-23 close of $303.53 corresponds to about $252 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
Valuation flags
- Overvalued by 21%
- Misses analyst estimates often (45%)
Frequently asked questions
Is LGND overvalued?
At a current P/E of 33.3 versus its historical normal P/E of 27.6, LGND trades about 21% above its typical valuation, with a PEG of 1.46 on 22.8% forward growth. tickerseer currently rates it trading above its usual valuation.
What is LGND's fair value and PEG?
LGND trades at a current P/E of 33.3 against a historical normal P/E of 27.6, a PEG of 1.46, and a forward growth estimate of 22.8%. Priced at its historical normal P/E of 27.6 on the same blended earnings, the 2026-10-23 close of $303.53 corresponds to about $252 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of LGND changed?
tickerseer's rating has been trading above its usual valuation since 2026-10-24.
Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.